Journal of Clinical Oncology
Articles in this Issue
Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC): The K-COMPASS model.
537 Background: Biomarkers do not yet exist to triage patients with oligometastatic ccRCC for de-escalation strategies. Tw...
Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in patients with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444).
737 Background: Many pts with MIBC are not candidates for radical cystectomy (RC) and/or favor bladder-sparing alternative...
Pathologic response after neoadjuvant therapy in renal cell carcinoma using irRVT criteria.
549 Background: Pathologic response after neoadjuvant therapy for renal cell carcinoma (RCC) lacks a standardized system t...
Real-world patient characteristics and treatment patterns among patients with metastatic castration-resistant prostate cancer treated with talazoparib plus enzalutamide in the US.
121 Background: Talazoparib plus enzalutamide (tala+enza) was approved by FDA in June 2023 for homologous recombination re...
IMGeS study: A prospective, multicentre, phase II trial of sequential intravesical mitomycin-C and gemcitabine therapy in BCG-unresponsive high-risk NMIBC ineligible for or declining radical cystectomy.
TPS904 Background: High-risk non-muscle-invasive bladder cancer (HR-NMIBC) unresponsive to adequate Bacillus Calmette-Guér...
Evaluating frailty and quality of life in low-income, uninsured men with prostate cancer.
334 Background: We evaluated frailty across multiple domains and examined its association with prostate cancer (PCa)-speci...
Association of pre-operative circulating tumor DNA (ctDNA) status with clinicopathologic characteristics in patients (pts) with localized renal cell carcinoma (RCC).
532 Background: Clinicopathologic nomograms, such as UISS, Leibovich, and SSIGN models, are used to estimate recurrence ri...
Assistance of a large language model–based AI agent in preoperative communication for reduction of prostate cancer patients' anxiety and clinicians' burden: A prospective, randomized, single-blinded, phase II trial.
56 Background: Preoperative communication is crucial in reducing patients' anxiety but demands considerable effort from cl...
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
TPS623 Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly x 4 is standard first-line chemotherapy for in...
Oncological outcomes of primary retroperitoneal lymph node dissection in patients with clinical stage IIB seminoma: A binational retrospective analysis.
609 Background: Primary retroperitoneal lymph node dissection (pRPLND) is emerging as a first-line treatment option for st...
Cardiovascular toxicity with androgen-receptor pathway inhibitors in metastatic prostate cancer: A meta-analysis of randomized trials.
145 Background: Multiple trials have demonstrated addition of androgen-receptor pathway inhibitors (ARPIs) improve surviva...